OnFebruary 25, Professor Young hak Kim, Associate Professor at Thoracic Oncology of Kyoto University, Doctor of Medicine, Doctor of Philosophy, ASCO member, IASLC member, ESMO member, standing member of Japanese Internal Medical Association, standing member of Japanese Respiratory Medical Association, and standing member of Japanese Cancer Therapy Medical Association, made academic communication with oncologists and researchers of our hospital on “NSCLC targeted therapy”.
Professor Kim came to our hospital at the invitation of Professor Li Enxiao, Director of Medical Oncology Department. This academic communication aimed to understand the current situation of NSCLC treatment and the actual treatment status of patients in Japan. The attendees conducted in-depth discussions and relaxed exchanges on the topic of “targeted therapy of lung cancer”.
Professor Kim briefed about medical treatment environment, ratio of nurses to doctors, and management situation in Japan. Experts from both sides conducted in-depth discussions and communications on the specific clinical issues regarding application of targeted therapy in Japan, such as dosage of anti-angiogenesis targeted drug, adaptation disease, and contraindication, matters that need to pay close attention during actual operation process, drug fast, toxic and side effect, and maintenance treatment. Professor Kim also touched on NSCLC targeted treatment, especially patient screening, curative effect evaluation, and follow-up visit during the application of anti-angiogenesis treatment, which has provided valuable reference for us in improving and strengthening the clinical application of lung cancer molecular targeted drug. In addition, he has given honest advice on clinical scientific research and selection of research direction.
After the meeting, Professor Li Enxiao thanked Professor Kim for coming to share his experience with us and he hoped the communication could deepen mutual understanding, help to learn from each other and improve diagnosis and treatment level. Professor Kim expressed his willingness to see our oncologists and physicians in Japan for academic communication, thus further promoting the international cooperation and technical exchanges on anti-tumor treatment and relative research work.
